Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Rises By 1,724.4%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large increase in short interest in June. As of June 30th, there was short interest totaling 82,827 shares, an increase of 1,724.4% from the June 15th total of 4,540 shares. Based on an average daily volume of 262,246 shares, the short-interest ratio is presently 0.3 days. Currently, 1.8% of the shares of the company are sold short.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC boosted its holdings in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned about 3.59% of Sonoma Pharmaceuticals worth $222,000 as of its most recent SEC filing. 1.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA stock remained flat at $1.26 during trading on Friday. 101,758 shares of the stock traded hands, compared to its average volume of 173,805. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $6.92. The company has a market capitalization of $6.04 million, a price-to-earnings ratio of -0.67 and a beta of 1.27. The firm’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $2.22.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The company had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.